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4-Methylmethcathinone (4-MMC, mephedrone) is a substituted synthetic cathinone
(β-keto amphetamine) that has recently become popular as a party drug (Dargan et al., 2010; Green et al., 2014) . Mephedrone was widely sold as a "legal high" and continued to be available on the illicit drug market after being classified as illegal (Green et al., 2014; Wood et al., 2012) . Structurally and pharmacologically similar new psychoactive substances (NPS) have emerged on the drug market as legal alternatives to the newly banned mephedrone (Brandt et al., 2010) . Knowledge of the effects and toxicity of NPS is often solely based on user reports and clinical intoxication cases, and pharmacological and toxicological data are mostly lacking. Therefore, the assessment of in vitro pharmacological profiles of NPS is a first approach to better understand their clinical effects and toxicology. In the present study, we assessed monoamine transporter and receptor interaction profiles of a new series of mephedrone analogs and related designer drugs ( Fig. 1 ) and compared them to mephedrone.
Several of the tested substances were first described in the 20th century, but the widespread availability and recreational use of these substances is a rather recent phenomenon (Baumeister et al., 2015; Brandt et al., 2014; Liechti, 2015) . The substituted M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 5 associated with numerous fatal and non-fatal intoxications in recent years (Backberg et al., 2014; Katselou et al., 2015; Kronstrand et al., 2013; Seetohul and Pounder, 2013) . 5-IT has been shown to be a substrate at the transporter for norepinephrine (NET), dopamine (DAT), and serotonin (SERT) in rat brain synaptosomes with greater potency for release at NET and DAT over SERT (Marusich et al., 2016) . Moreover, 5-IT produced locomotor stimulation and stimulant effects similar to 3,4-methylenedioxymethamphetamine (MDMA) in mice (Marusich et al., 2016) . 4-Methylamphetamine (4-MA) is an NPS that has been detected in street amphetamine ("speed") samples across Europe and was linked to several fatalities in combination with amphetamine (Blanckaert et al., 2013) . In a study comparing the monoamine releasing potencies of a series of amphetamines analogs in vitro, 4-MA and damphetamine had similar potencies as releasers of norepinephrine (NE) and dopamine (DA), but 4-MA was a more potent releaser of serotonin (5-HT) (Wee et al., 2005) . 4-MA was selfadministered at a lower rate by rhesus monkeys compared to d-amphetamine (Wee et al., 2005) .
N-methyl-2-aminoindane (N-methyl-2-AI) and 5-methoxy-6-methyl-2aminoindane (MMAI) are two psychoactive aminoindanes that have been sold as designer drugs online. MMAI has previously been shown to have effects on the SERT similar to MDMA (Rudnick and Wall, 1993 ) and a high selectivity for 5-HT vs. NE and DA uptake inhibition (Johnson et al., 1991) .
Material and methods
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Monoamine uptake transport inhibition
Inhibition of the human NE, DA, and 5-HT transporter (hNET, hDAT, and hSERT, respectively) was assessed in human embryonic kidney (HEK) 293 cells (Invitrogen, Zug, Switzerland) stably transfected with the respective human transporter as previously described (Hysek et al., 2012; Tatsumi et al., 1997 Thereafter, 100 µl of the cell suspension was transferred to 500 µl microcentrifuge tubes that the cell pellet was then cut into 6 ml scintillation vials (Perkin-Elmer) that contained 0.5 ml lysis buffer (0.05 M TRIS-HCl, 50 mM NaCl, 5 mM EDTA, and 1% NP-40 in water). The samples were shaken for 1 h before 5 ml scintillation fluid (Ultimagold, Perkin Elmer, Schwerzenbach, Switzerland) was added. Monoamine uptake was then quantified by liquid scintillation counting on a Packard Tri-Carb Liquid Scintillation Counter 1900 TR.
Nonspecific uptake in the presence of selective inhibitors was subtracted from the total counts.
Transporter-mediated monoamine release
Transporter-mediated monoamine efflux was assessed in HEK 293 cells stably expressing the respective transporter as previously described (Simmler et al., 2013; Simmler et al., 2014a) . Briefly, 100,000 cells per well were cultured overnight in a poly-D-lysine coated XF24 cell culture microplate (Seahorse Biosciences, North Billerica, MA, USA).
Thereafter, the cells were preloaded with 10 nM release and subsequent reuptake inhibition (Scholze et al., 2000) . The use of a single high concentration and the release durations were based on kinetic evaluation of the release-overtime curves for substrate-releasers in previous studies (Hysek et al., 2012; Simmler et al., 2014a) .
Radioligand receptor and transporter binding assays
The radioligand binding assays were performed as previously described in detail for transporters (Hysek et al., 2012) and receptors (Revel et al., 2011) . Briefly, HEK 293 cell membrane preparations (Invitrogen, Zug, Switzerland) overexpressing the respective transporters (Tatsumi et al., 1997) or receptors (human genes except rat and mouse genes for trace amine-associated receptors [TAARs]) (Revel et al., 2011) were incubated with radiolabeled selective ligands at concentrations equal to K d and ligand displacement by the compounds was measured. The difference between the total binding and nonspecific binding that was determined in the presence of the selected competitors in excess, was defined as specific binding of the radioligand to the target. The following radioligands and competitors, 
Activity at the serotonin 5-HT 2A receptor
Mouse embryonic fibroblasts (NIH-3T3 cells) expressing the human 5-HT 2A receptor were incubated in HEPES-Hank's Balanced Salt Solution (HBSS) buffer (Gibco; 70,000 cells/100 µl) for 1 h at 37 °C in 96-well poly-D-lysine-coated plates. To each well, 100 µl dye solution (fluorescence imaging plate reader [FLIPR] calcium 5 assay kit; Molecular Devices, Sunnyvale, CA, USA) was added and the plates were incubated for 1 h at 37 °C. The plates were placed in a FLIPR and 25 µl of the test drugs diluted in HEPES-HBSS buffer containing 250 mM probenicid were added online. The increase in fluorescence was then measured and EC 50 values were derived from the concentration-response curves using nonlinear regression.
The maximal receptor activity (efficacy) is expressed relative to 5-HT activity, which was set to 100%.
Activity at the serotonin 5-HT 2B receptor
HEK 293 expressed relative to 5-HT activity, which was set to 100%.
Cytotoxicity
Cytotoxicity in hSERT-, hDAT-, and hNET-transfected HEK 293 cells was assessed with the ToxiLight bioassay kit (Lonza, Basel, Switzerland) according to the manufacturer's protocol. The cells were treated for 1 h at room temperature with the drugs at the highest assay concentrations. Adenylate kinase release as a result of cell membrane integrity loss was then quantified and compared to control.
Statistical analysis
Monoamine uptake data were fit by nonlinear regression to variable-slope sigmoidal 
Monoamine uptake transporter inhibition
IC 50 values for NET, DAT, and SERT inhibition are listed in Table 1, 
Monoamine release
Monoamine efflux at a 100 µM concentration of the test drugs is shown in Fig. 3 . All of the cathinones were releasers of all three monoamines, with the exception of 3,4-DMMC, for which 5-HT release was not significantly higher than the inhibitor control. 5-IT caused DA and 5-HT efflux. 4-MA caused NE, DA, and 5-HT efflux. N-methyl-2-AI was a selective NE releaser. MMAI was a selective 5-HT releaser.
Monoamine receptor and transporter binding affinities
The monoamine receptor and transporter binding affinities and receptor activation potentials of the mephedrone analogs and related designer drugs are shown in Table 2 
Cytotoxicity
None of the drugs were cytotoxic up to 1 h at the investigated concentrations, thus confirming cell integrity during the functional assays.
Discussion
Monoamine uptake transporter inhibition
Similar to mephedrone, the novel mephedrone analogs potently inhibited the NET, which likely results in similar sympathomimetic stimulation (Hysek et al., 2011) . The crucial role of NE in the acute effects of psychostimulants is supported by the finding that the release of NE but not DA correlates with human doses of amphetamine-type stimulants (Rothman et al., 2001) . Additionally, NET inhibition potency values strongly correlated with the psychotropic effective doses of psychostimulants including cathinones in humans (Simmler et al., 2013) . Furthermore, NE has been shown to contribute to the acute subjective stimulation and cardiovascular effects of MDMA in humans (Hysek et al., 2011) . (Hysek et al., 2011) 3-MMC more potently inhibited the DAT than the SERT. Mephedrone (4-MMC) had similar potency at the DAT and SERT as previously shown in some other studies (Baumann et al., 2012; Hadlock et al., 2011; Simmler et al., 2013) , while others found 5-10-fold higher potency at the DAT vs. SERT (Eshleman et al., 2013; Mayer et al., 2016; Pifl et al., 2015) .
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13 Moreover, the present high NET vs. DAT selectivity of mephedrone was not or less observed in some other studies (Eshleman et al., 2013; Mayer et al., 2016; Pifl et al., 2015) . While the selectivity of mephedrone for the NET over the SERT in our study is similar to other in vitro studies (Eshleman et al., 2013; Mayer et al., 2016; Pifl et al., 2015) , the NET over DAT selectivity appears to be higher compared with other labs. This has been observed for mephedrone in previous studies of our lab (Rickli et al., 2015a; Simmler et al., 2013) ,
suggesting that those differences may be explained by differences in the experimental design or the transfected cell line.
The dimethylmethcathinones inhibited the SERT more potently than the DAT. These results suggest that 3-MMC has stronger amphetamine-like stimulant properties compared with mephedrone and especially the other more serotonergic dimethylmethcathinones.
Stimulant toxicity was reported to be the main clinical feature in patients with recreational 3-MMC intoxication, although often combined with other drugs (Backberg et al., 2015) .
Dimethylmethcathinones presumably have entactogenic properties that are similar to MDMA because of greater activation of the 5-HT system (Hysek et al., 2012; Simmler et al., 2013) .
High selectivity for the SERT vs. DAT was also observed for the para-substituted 4-MA, whereas previous studies found high inhibition selectivity for the DAT vs. SERT for amphetamine (Rickli et al., 2015a; Simmler et al., 2013) . The strong serotonergic activity of 4-MA has been hypothesized to decrease its reinforcing potency compared with other amphetamine analogs (Baumann et al., 2011; Wee et al., 2005) . However, the strong serotonergic activity of 4-MA may have led to several fatal cases when combined with the strong dopaminergic activity of amphetamine in users of 4-MA contaminated "speed" (Blanckaert et al., 2013) . Moreover, the extreme hyperthermia that is observed in such patients may be explained by the strong serotonergic potency of 4-MA, which is not shared by amphetamine (Blanckaert et al., 2013) . 5-IT was a very potent inhibitor of the NET, with M A N U S C R I P T
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14 potent inhibition also of the DAT and SERT. 5-IT has been associated with sympathomimetic and serotonergic toxicity and was involved in numerous deaths across Europe (Backberg et al., 2014; Katselou et al., 2015; Kronstrand et al., 2013; Seetohul and Pounder, 2013) . Nmethyl-2-AI selectively inhibited the NET, with very weak inhibition potency for the DAT and SERT, suggesting mild psychoactive effects that are similar to 2-aminoindane (2-AI) (Simmler et al., 2014b) . MMAI had NET inhibition potencies that were similar to N-methyl-2-AI. Unlike N-methyl-2-AI, however, MMAI potently inhibited the SERT at submicromolar concentrations.
Monoamine release
Consistent with previous studies, mephedrone caused efflux of all three monoamines (Baumann et al., 2012; Eshleman et al., 2013; Mayer et al., 2016) . The cathinone analogs of mephedrone were also monoamine releasers, indicating that they are monoamine transporter substrates like most amphetamines (Sitte and Freissmuth, 2015) . One exception was 3,4-DMMC, which was a potent inhibitor of the SERT but did not cause significant 5-HT efflux.
The monoamine transporter inhibition profile of 3,4-DMMC is similar to MDMA (Simmler et al., 2013) , but their differences in 5-HT release may partially explain their different subjective effects and potency. 4-MA released all three monoamines as described for amphetamine (Rickli et al., 2015a) . 5-IT was a very potent inhibitor of the NET, but NE release was not observed. N-methyl-2-AI selectively inhibited the NET and was also a selective NE releaser. MMAI was a highly selective 5-HT releaser, consistent with previous reports Nichols, 1994, 1998) . The high serotonergic activation by MMAI suggests entactogenic effects. However, the lack of any effect on the DA or NE system indicates that the psychopharmacology of MMAI differs from typical entactogens like MDMA (Marona-Lewicka and Nichols, 1994) .
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Receptor-binding profiles
All of the drugs potently bound to adrenergic receptors, which are known to modulate stimulant-induced behavior (Schmidt and Weinshenker, 2014) . Furthermore, the drugs interacted with several serotonin receptors. All of the compounds bound to the 5-HT 2A receptor as previously shown for mephedrone and MDMA (Eshleman et al., 2013; Simmler et al., 2013) and typically for serotonergic hallucinogens (Eshleman et al., 2014; Nichols, 2016; Rickli et al., 2015c; Rickli et al., 2016) . Additionally, 2,3-DMMC, mephedrone, and 5-IT were potent functional 5-HT 2A agonists in our calcium mobilization assay like MDMA (Rickli et al., 2015b) and classic serotonergic hallucinogens (Rickli et al., 2016) known to produce their psychotropic effects at least in part via 5-HT 2A receptor activation (Liechti et al., 2000; Preller et al., 2017; Vollenweider et al., 1998) . Another study documented 5-HT 2A receptor antagonistic properties for mephedrone in another 5-HT-induced inositol monophosphate formation assay (Eshleman et al., 2013) . However, MDMA had both agonist (Eshleman et al., 2014) and antagonist effects (Eshleman et al., 2013) in this assay indicating that the 5-HT 2A ligands may act as agonist and antagonists depending on assay set-up.
Certain hallucinogenic properties have been described for mephedrone (Kasick et al., 2012; Schifano et al., 2011) and our results suggest that 2,3-DMMC could have hallucinogen-like properties as well. 5-IT is a positional isomer of the psychedelic tryptamine αmethyltryptamine (αMT). 5-IT has been previously suggested to also have hallucinogenic properties (Marusich et al., 2016) , and its potent 5-HT 2A receptor activation supports this possibility. All of the substances interacted with rat and mouse TAARs. Many stimulant NPS interact with TAARs (Simmler et al., 2016) , which have a modulatory role on monoaminergic activity (Revel et al., 2012; Revel et al., 2011) . In a recent screening of a large set of NPS, cathinones were described as poor TAAR1 ligands (Simmler et al., 2016) .
Our results suggest that this does not apply to all cathinones as submicromolar affinity for rat and mouse TAARs was observed for 2,4-DMMC and 2,3-DMMC, respectively.
The present study has limitations. First, we did not investigate the effects of the drugs on intracellular targets such as the vesicular monoamine transporter 2 (VMAT2). Lower potency VMAT2 interactions have been reported for methcathinones compared to MDMA and methamphetamine (Eshleman et al., 2013; Fleckenstein et al., 2009; Pifl et al., 2015) . It was therefore concluded that mephedrone is unlikely to cause neurotransmitter release form synaptic vesicles (Eshleman et al., 2013) . Second, the static monoamine release assay used in the present study was only useful to qualitatively determine whether a drug is a substrate releaser or not, but the assay was not suitable to assess the potency of the releasers.
Superfusion assays would be more suitable to also determine the potency of the substances to release monoamines (Eshleman et al., 2013) . However, the potency of the substances to release monoamine is reflected by their potency to inhibit monoamine uptake in the uptake assay used in the present study (Simmler et al., 2013) . Finally, we included no in vivo data.
However, in vivo microdialysis studies showed that the cathinones mephedrone and methylone markedly released both 5-HT and DA at similar potencies reflecting their in vitro pharmacological profiles (Baumann et al., 2012; Kehr et al., 2011) . Additionally, methcathinone was a more potent inhibitor of the DAT than SERT in vitro, more potently released monoamines via the DAT than SERT (Cozzi et al., 2013; Simmler et al., 2013) , and consistently also more potently increased extracellular DA than 5-HT in rat brain nucleus accumbens dialysate (Cozzi et al., 2013) . Vice versa, the more potent in vitro SERT than DAT inhibitor and predominant 5-HT releaser 4-trifluoromethylmethcathinone (4-TFMAP)
increased 5-HT but not DA in vivo (Cozzi et al., 2013) . Thus, for several cathinones the in vitro profiles accurately predicted the in vivo neurochemical effects. 
Conclusion
The present study characterized a series of novel mephedrone analogs that potently interacted with monoamine transporters and receptors, suggesting their potential abuse liability, which has been previously observed for synthetic cathinones. 4-MA is a potent inhibitor of the SERT, which may explain its higher toxicity when combined with the potent DAT inhibitor amphetamine. 5-IT is a highly potent monoamine transporter inhibitor that has been associated with sympathomimetic toxicity and numerous fatalities across Europe. Nmethyl-2-AI is a selective NET inhibitor and NE releaser, and MMAI is a selective SERT inhibitor and 5-HT releaser. 
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